Aveanna Healthcare Hldgs Azioni (NASDAQ: AVAH)

Ultime notizie per Aveanna Healthcare Hldgs (NASDAQ:AVAH) Azioni

Aveanna Healthcare Hldgs

Aveanna Healthcare Holdings Inc is a diversified home care platform that provides care to medically complex, high-cost patient populations. It directly addresses the pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home. The firm provides its services through three segments: Private Duty Services (PDS); Home Health & Hospice (HHH); and Medical Solutions (MS). Private Duty Services include private duty nursing (PDN) and pediatric therapy services. Revenue is primarily derived from pediatric healthcare services provided to patients including private duty nursing and therapy services, adult home health and hospice services (collectively patient revenue) and from the delivery of enteral nutrition and other products to patients.

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Holdings Inc

Tidewater (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDW#NYSE">TDW</a>) reported quarterly earnings of $0.87 per share which missed the analyst consensus estimate of $1.09 by 20.18 percent. This is a 77.55 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $340.40 million which missed the analyst consensus estimate of $345.55 million by 1.49 percent. This is a 13.75 percent increase over sales of $299.26 million the same period last year.

Earnings

Earnings Misses

News

Tidewater Q3 EPS $0.87 Misses $1.09 Estimate, Sales $340.40M Miss $345.55M Estimate

Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 56.52 percent. This is a 96.85 percent increase over losses of $(3.17) per share from the same period last year.

Earnings Beats

SKYE

Skye Bioscience Q3 2024 GAAP EPS $(0.10) Beats $(0.23) Estimate

Victory Capital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCTR#NASDAQ">VCTR</a>) reported quarterly earnings of $1.35 per share which beat the analyst consensus estimate of $1.30 by 3.85 percent. The company reported quarterly sales of $225.60 million which beat the analyst consensus estimate of $224.31 million by 0.58 percent. This is a 7.59 percent increase over sales of $209.69 million the same period last year.

VCTR

Victory Capital Holdings Q3 2024 Adj EPS $1.35 Beats $1.30 Estimate, Sales $225.60M Beat $224.31M Estimate

Consensus Cloud Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) reported quarterly earnings of $1.31 per share which beat the analyst consensus estimate of $1.29 by 1.55 percent. The company reported quarterly sales of $87.753 million which beat the analyst consensus estimate of $85.332 million by 2.84 percent. This is a 3.10 percent decrease over sales of $90.562 million the same period last year.

CCSI

Consensus Cloud Solutions Q3 2024 Adj. EPS $1.31 Beats $1.29 Estimate, Sales $87.753M Beat $85.332M Estimate

Q4 2024 Financial Outlook
For the fourth quarter of 2024, we expect total revenue to be in the range of $72 million to $76 million, of which approximately $11 million is expected to be tools revenue. We expect GAAP diluted EPS to be in the range of $(0.12) to $(0.06) and non-GAAP diluted EPS to be in the range of $(0.10) to $(0.04).
This outlook for non-GAAP diluted EPS excludes anticipated equity-based compensation expense of approximately $2.0 million. Non-GAAP diluted EPS should be considered in addition to, but not as a substitute for, our financial information presented in accordance with GAAP.

Guidance

SKYT

SkyWater Technology Sees Q4 EPS $(0.10) - $(0.04) Vs $(0.03) Est.; Revenue $72M-$76M Vs $79.97M Est.

Airbnb Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) reported third-quarter financial results Thursday after the bell. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/11/n41823683/airbnb-announces-third-quarter-2024-results">rundown of the report</a>.
Q3 Earnings: Airbnb reported third-quarter revenue of $3.70 billion, missing the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $3.72 billion. The company reported third-quarter earnings of $2.13 per share, missing analyst estimates of $2.16 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue was up 10% year-over-year. Gross booking value totaled $20.1 billion, up 10% year-over-year. Nights and Experiences booked came in at $122.8 million, up 8% year-over-year.
Airbnb said it generated $1.1 billion of free cash flow during the quarter. The company ended the quarter with $11.3 billion in cash, cash equivalents, short-term investments and&nbsp;restricted cash.
&#8220;Airbnb had a strong Q3. Nights and Experiences Booked accelerated throughout the quarter and into Q4, despite a softer start due to shorter booking lead times compared to 2023,&#8221; the company said in a letter to shareholders.
&#8220;Building on robust momentum in September, we are off to a great start in fourth quarter 2024. We are seeing strong demand trends in Q4 2024 across core and expansion markets for both long and short lead times.&#8221;
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41820744/9-stocks-to-watch-financial-sector-outshines-tech-in-2024-as-trump-trade-sparks-m-a">9 Stocks To Watch: Financial Sector Outshines Tech In 2024 As &#8216;Trump Trade&#8217; Sparks M&amp;A Optimism</a>
Outlook:&nbsp;Airbnb expects fourth-quarter revenue to be in the range of $2.39 billion to $2.44 billion. The company expects Nights and Experiences booked in the fourth quarter to be higher than in the third quarter. 
Airbnb anticipates full-year 2024 adjusted EBITDA margin of approximately 35.5% The company expects full-year free cash margin to be &#8220;several points above&#8221; adjusted EBITDA margins.
Airbnb executives will discuss the company&#8217;s quarterly results on a call with analysts and investors at 4:30 p.m. ET.
ABNB Price Action: <a href="https://www.benzinga.com/quote/ABNB" target="_blank" rel="noreferrer noopener">Airbnb shares</a> were down 2.08% in after-hours, trading at $142.50 at the time of publication Thursday, according to <a href="http://pro.benzinga.com" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41820253/fed-cuts-interest-rates-to-lowest-since-february-2023-sticks-to-data-driven-path"> • Fed Cuts Interest Rates To Lowest Since February 2023, Sticks To Data-Driven Path (CORRECTED)</a>
Photo: Shutterstock.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Airbnb Q3 2024 Earnings Call &#x7C; $ABNB" width="500" height="281" src="https://www.youtube.com/embed/RR_D086agzA?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Travel

After-Hours Center

Movers

General

ABNB

Airbnb Stock Down On Q3 Earnings: 'Building On Robust Momentum In September, We Are Off To A Great Start In Q4'

Collegium Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLL#NASDAQ">COLL</a>) reported quarterly earnings of $1.61 per share which beat the analyst consensus estimate of $1.59 by 1.26 percent. This is a 20.15 percent increase over earnings of $1.34 per share from the same period last year. The company reported quarterly sales of $159.30 million which beat the analyst consensus estimate of $155.57 million by 2.40 percent. This is a 16.53 percent increase over sales of $136.71 million the same period last year.

COLL

Collegium Pharmaceutical Q3 Adj $1.61 Beats $1.59 Estimate, Sales $159.30M Beat $155.57M Estimate

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) affirms FY2024 sales outlook from $140.00 million-145.00 million to $140.00 million-145.00 million.

CUTR

Cutera Affirms FY2024 Sales Guidance to $140.00M-145.00M  VS Est.141.53M

Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) lowers FY2024 sales outlook from $450.00 million-470.00 million to $440.00 million-455.00 million.

PRCH

Porch Group Lowers FY2024 Sales Guidance from $450.00M-470.00M to $440.00M-455.00M

BILL

BILL Holding Sees FY25 Adj. EPS $1.65-$1.83 Vs $1.55 Est.; $1.439B-$1.464B Vs $1.437B

Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) reported $354.41 thousand in sales this quarter. This is a 115.91 percent increase over sales of $164.15 thousand the same period last year.

REFR

Research Frontiers Q3 Sales $354.41K Up From $164.15K YoY

BILL Holding Sees Q2 Adj. EPS $0.44-$0.48; Revenue $355.5M-$360.5M

ProAssurance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.14 by 142.86 percent. The company reported quarterly sales of $285.25 million which missed the analyst consensus estimate of $316.34 million by 9.83 percent. This is a 17.67 percent increase over sales of $242.42 million the same period last year.

ProAssurance Q3 2024 Adj EPS $0.34 Beats $0.14 Estimate, Sales $285.25M Miss $316.34M Estimate

Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) affirms FY2024 sales outlook from $410.00 million-425.00 million to $410.00 million-425.00 million.

BRLT

Brilliant Earth Group Affirms FY2024 Sales Guidance from $410.00M-425.00M to $410.00M-425.00M

Mettler-Toledo Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTD#NYSE">MTD</a>) reported quarterly earnings of $10.21 per share which beat the analyst consensus estimate of $10.01 by 2 percent. The company reported quarterly sales of $954.53 million which beat the analyst consensus estimate of $944.74 million by 1.04 percent. This is a 1.28 percent increase over sales of $942.46 million the same period last year.

Mettler-Toledo Intl Q3 2024 Adj EPS $10.21 Beats $10.01 Estimate, Sales $954.53M Beat $944.74M Estimate

Consensus Cloud Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCSI#NASDAQ">CCSI</a>) affirms FY2024 Adj EPS guidance from $5.45-5.55 to $5.45-5.55 vs $5.50 analyst estimate. Narrows FY2024 sales outlook from $338.00 million-353.00 million to $346.00 million-350.00 million vs $344.10 million estimate.

Consensus Cloud Solns Affirms FY2024 Adj EPS Guidance from $5.45-5.55 to $5.45-5.55 vs $5.50 Est; Narrows FY2024 Sales Guidance from $338.00M-353.00M to $346.00M-350.00M vs $344.10M Est

Outlook2
For the fourth quarter ending December 31, 2024, Toast expects to report:
<ul>
<li>Non-GAAP subscription services and financial technology solutions gross profit in the range of $370 million to $380 million (32-35% growth compared to Q4 2023)</li>
<li>Adjusted EBITDA in the range of $90 million to $100 million</li>
</ul>
For the full year ending December 31, 2024, Toast expects to report:
<ul>
<li>Non-GAAP subscription services and financial technology solutions gross profit in the range of $1,395 million to $1,405 million (32-33% growth compared to 2023, up from 27-29% growth)</li>
<li>Adjusted EBITDA in the range of $352 million to $362 million (up from $285 million to $305 million)</li>
</ul>
The outlook provided above constitutes forward-looking information within the meaning of applicable securities laws and is based on a number of assumptions and subject to a number of risks. See cautionary note regarding "Forward-looking Statements" in this press release.

TOST

Toast Sees Q4 Non-GAAP Subscription Services And Financial Technology Solutions Gross Profit In The Range Of $370M-$380M; FY24 Non-GAAP Subscription Services And Financial Technology Solutions Gross Profit In The Range Of $1.395B-$1.405B

Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.33) by 3.03 percent.

ALLO

Allogene Therapeutics Q3 2024 GAAP EPS $(0.32) Beats $(0.33) Estimate

Green Thumb Industries (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.06 by 33.33 percent. This is a 20 percent decrease over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $286.87 million which beat the analyst consensus estimate of $282.56 million by 1.52 percent. This is a 4.16 percent increase over sales of $275.40 million the same period last year.

GTBIF

Green Thumb Industries Q3 EPS $0.04 Misses $0.06 Estimate, Sales $286.87M Beat $282.56M Estimate

NV5 Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEE#NASDAQ">NVEE</a>) lowers FY2024 Adj EPS guidance from $5.13-5.20 to $1.15-1.19 vs $1.29 analyst estimate. Lowers FY2024 sales outlook from $944.00 million-950.00 million to $939.00 million-943.00 million vs $946.02 million estimate.

NVEE

NV5 Global provides FY2024 guidance: Gross revenues $939M-$943M (est. 946.02M); GAAP EPS $0.48-$0.54 (est. 0.67); Adj. EPS $1.15-$1.19 (adjusted for 4-1 stock split) vs (est. 1.29)

An update from Aveanna Healthcare Holdings (AVAH) is now available. Aveanna Healthcare Holdings Inc. has released a financial presentation for inve...

Aveanna Healthcare Shares Investor Presentation Update

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on GeoVax Labs (GOVX – Research Report), Akebia Thera...

Analysts Have Conflicting Sentiments on These Healthcare Companies: GeoVax Labs (GOVX), Akebia Therapeutics (AKBA) and Aveanna Healthcare Holdings (AVAH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on AMN Healthcare Services (AMN – Research Report), Verona Pharma (V...

Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN), Verona Pharma (VRNA) and Aveanna Healthcare Holdings (AVAH)

Aveanna Healthcare files for $400M mixed securities shelf

Truist Financial analyst Jailendra Singh maintained a Hold rating on Aveanna Healthcare Holdings (AVAH – Research Report) today. The company's shar...

Truist Financial Keeps Their Hold Rating on Aveanna Healthcare Holdings (AVAH)

Aveanna Healthcare Holdings ( ($AVAH) ) has shared an update. Aveanna Healthcare has successfully amended its First Lien Credit Agreement, extendin...

Aveanna Healthcare Bolsters Liquidity with Credit Agreement Extension

Aveanna Healthcare Holdings ( ($AVAH) ) just unveiled an update. Aveanna Healthcare Holdings Inc. has appointed Brent Layton as a Class III directo...

Aveanna Healthcare Appoints Brent Layton to Board

The latest announcement is out from Aveanna Healthcare Holdings ( ($AVAH) ). Aveanna Healthcare Holdings reported robust financial growth for Q3 20...

Aveanna Healthcare Sees Revenue Growth Despite Net Loss

Reports Q3 revenue $509.0M, consensus $496.02M. CEO Jeff Shaner commented, "We have delivered another strong operating and financial quarter, highl...

Aveanna reports Q3 adjusted EPS 2c, consensus (1c)

Raises 2024 adjusted EBITDA view to greater than $168M from greater than $158M. Published first on TheFly – the ultimate source for real-time, mark...

Aveanna raises 2024 revenue view to $2.0B from above $1.985B, consensus $1.99B

AKBA

AVAH

GOVX

VRNA

Press Releases

Aveanna to Participate at the Barclays Leveraged Finance Conference

Aveanna Healthcare Holdings Announces First Quarter 2024 Financial Results and Revised 2024 Outlook

Aveanna to Participate at the UBS Healthcare Services Cape Cod Summit and Jefferies Global Healthcare Conference

Aveanna Announces Second Quarter 2024 Earnings Release Date and Conference Call

Aveanna Healthcare Holdings Announces Second Quarter 2024 Financial Results and Revised 2024 Outlook

Aveanna to Participate at the Deutsche Bank Annual Leveraged Finance Conference

Aveanna Announces Third Quarter 2024 Earnings Release Date and Conference Call

Aveanna to Participate Virtually at the Stephens Annual Investment Conference

Management

Aveanna Healthcare Holdings Announces Appointment of New Director

Aveanna Healthcare Holdings Announces Third Quarter 2024 Financial Results and Revised 2024 Outlook

Accolade

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

AMN Healthcare Services

Astrana Health

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

Castle Biosciences

DocGo

Enhabit

Fulgent Genetics

InnovAge Holding

LifeStance Health Group, Inc. - Common Stock

LifeStance Health Gr

Pediatrix Medical Group, Inc. Common Stock

Pediatrix Medical Group

NeoGenomics

National Research Corporation - Common Stock

National Research

OPKO Health

Performant Financial Corporation - Common Stock

Performant Finl

Premier

Pennant Gr

Privia Health Gr

SBC Medical Group Holdings Incorporated - Common Stock

SBC Medical Group Holding

Talkspace

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Hldgs

RBC Capital

Deutsche Bank

Credit Suisse

Truist Securities

WIIM

Aveanna Healthcare Holdings shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 sales guidance above estimates.

Comments

Aveanna Healthcare Hldgs

Notizie

Ultime notizie per Aveanna Healthcare Hldgs (NASDAQ:AVAH) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO